发明名称 |
Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders |
摘要 |
The present invention relates to combination comprising (i) an ErbB inhibitor; and (ii) a CDK inhibitor, or a pharmaceutically acceptable salt thereof, selected from: (a) roscovitine; (b) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-pentan-2-ol; (c) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; and (d) (2R,3S-3-(6-((4,6-dimethylpyridin-3-ylmethylamino)-9-isopropyl-9H-purin-2-ylamino)pentan-2-ol.;Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising combinations according to the invention, and methods of treatment using the same. |
申请公布号 |
US9173938(B2) |
申请公布日期 |
2015.11.03 |
申请号 |
US200912573358 |
申请日期 |
2009.10.05 |
申请人 |
Cyclacel Limited |
发明人 |
Green Simon;Frame Sheelagh;Fleming Ian |
分类号 |
C07D473/34;A61K31/52;A61K45/06;A61K31/517 |
主分类号 |
C07D473/34 |
代理机构 |
Nelson Mullins Riley & Scarborough LLP |
代理人 |
Nelson Mullins Riley & Scarborough LLP ;Kanik Cynthia L. |
主权项 |
1. A combination comprising (i) an ErbB inhibitor or a pharmaceutically acceptable salt thereof; and (ii) roscovitine or a pharmaceutically acceptable salt thereof; wherein the ErbB inhibitor is selected from the group consisting of AG1478, erlotinib, gefitinib, and lapatinib. |
地址 |
London GB |